Strategic Transformation 2023

Strategic Transformation Toward Long-Term Vision (From the 2023 J.P. Morgan Healthcare Conference) Drive reni-cel (EDIT-301) toward BLA and Commercialization Platform Continue ex vivo development of reni-cel (EDIT- 301) for SCD, TDT Enroll 20 patients in RUBY study by year-end Provide RUBY and EdiTHAL data updates by mid-year and year-end Divest wholly-owned cell therapy program, continue supporting partnered cell therapy programs Terminate AAV IRD programs editas MEDICINE Strengthen and Focus Discovery to Build in vivo Editing Pipeline Focus on in vivo pipeline build Hire new CSO with specific expertise aligned with Editas' vision Reset discovery and technology group Initiate discovery of in vivo editing of HSCs and in other tissues Commercial Stage CH Increase Business Development Activities and Monetize IP Create value through business development to complement core gene editing technology capabilities Leverage robust IP portfolio Vertex sublicense for exa-cel Long-Term Vision: A Leader in In Vivo Programmable Gene Editing 5

View entire presentation